Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV

For HIV-infected children, formulation development, pharmacokinetic (PK) data, and evaluation of early toxicity are critical for licensing new antiretroviral drugs; direct evidence of efficacy in children may not be needed if acceptable safety and PK parameters are demonstrated in children. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, Deborah, Turner, Rebecca, Turkova, Anna, Penazzato, Martina, Musiime, Victor, Bwakura-Dangarembizi, Mutsa, Violari, Avy, Chabala, Chishala, Puthanakit, Thanyawee, Sudjaritruk, Tavitiya, Cressey, Tim R., Lallemant, Marc, Gibb, Diana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2018
Materias:
Supplement Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071856/
https://www.ncbi.nlm.nih.gov/pubmed/29994919
http://dx.doi.org/10.1097/QAI.0000000000001748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071856/
https://www.ncbi.nlm.nih.gov/pubmed/29994919
http://dx.doi.org/10.1097/QAI.0000000000001748

Ejemplares similares